BTK and pulmonary edema: We found that ibrutinib effectively suppressed poly I:C- and LPS-induced pulmonary edema, pro-inflammatory cytokine release, histopathological changes, neutrophil aggregation, lymphocyte aggregation, and activation of the BTK-, FLT3-, and EGFR-related signaling pathways.